To further support commonalities in the pathogenesis of T2D and T3D, there is evidence from clinical trials using anti-diabetic dugs (namely analogs of glucagon like peptide 1, GLP1) in patients with T2D and/or AD that demonstrate the amelioration of the cognitive performance in parallel with the improvement of the glucose metabolism [17]. This evidence concerns the gene GCG and Alzheimer disease.